Physician profile
Jack Waterman
NPI 1588623128
$1,674.12
in general payments reported to CMS, 2019-2025
26 companies · $19.85 in 2025
The $19.85 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $164 · 2021: $374 · 2022: $465 · 2023: $149 · 2024: $66.84 · 2025: $19.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $211 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $210.96 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $395.32 | 2019-2024 | Farxiga |
| Amgen INC. | $267.94 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.25 | 2021-2023 | |
| Vifor Pharma, INC. | $139.68 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.74 | 2019-2023 | Xifaxan |
| Mallinckrodt Enterprises LLC | $55.61 | 2019 | |
| Novo Nordisk INC | $52.73 | 2021-2023 | Wegovy |
| Travere Therapeutics, INC. | $50.95 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $50.74 | 2022-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $43.60 | 2022 | |
| Fresenius USA Marketing, INC. | $35.61 | 2023-2025 | Velphoro, Velphoro |
| Lilly USA, LLC | $34.87 | 2020-2023 | Jardiance |
| Amarin Pharma, INC. | $34.18 | 2019 | |
| Glaxosmithkline, LLC. | $34.14 | 2021-2023 | Benlysta |
| Arbor Pharmaceuticals, INC. | $34.10 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.27 | 2019 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Takeda Pharmaceuticals U.S.A., INC. | $24.60 | 2022 | |
| La Jolla Pharmaceutical Company | $22.59 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.59 | 2022 | |
| Eisai INC. | $20.24 | 2022 | |
| Genentech USA, INC. | $19.72 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.86 | 2020 | |
| Esperion Therapeutics, INC. | $18.63 | 2021 | |
| Genzyme Corporation | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Waterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.